Billing or Healing? UnitedHealth's HouseCalls Get a DOJ Checkup

UnitedHealth Group (UNH) is facing a criminal investigation by the U.S. Department of Justice into its Medicare Advantage billing practices, specifically probing whether its "HouseCalls" program used inflated diagnoses to secure higher federal payments. This criminal inquiry significantly escalates the stakes for the largest Medicare Advantage provider, potentially impacting billions in federal payments, UNH's reputation, and its core business model. The probe adds considerable pressure as UNH and its peers are already grappling with rising medical costs, leading UNH to withdraw its 2025 earnings guidance and its stock to underperform the industry.

Analysis

UnitedHealth Group (UNH) is facing a significant escalation of regulatory risk with the U.S. Department of Justice's launch of a criminal investigation into its Medicare Advantage billing practices. The probe, which focuses on potential upcoding within its "HouseCalls" program to inflate federal payments, represents a material threat to the largest player in the Medicare Advantage market. This legal challenge compounds existing operational headwinds, as the company had already withdrawn its 2025 earnings guidance in May amid industry-wide pressure from rising medical costs—a trend echoed by peers Molina Healthcare (MOH) and Centene (CNC), who have also cut or pulled their outlooks. Financially, UNH's stock reflects this distress, having declined 40.2% year-to-date and underperforming the broader industry's 31.1% drop. Despite this sell-off, the company trades at a forward P/E of 12.82, a premium to the industry average of 11.64, while the Zacks Consensus Estimate for its 2025 earnings points to a sharp 21% year-over-year decline, signaling that significant fundamental and legal risks persist.

Key Decisions for Investors

• Given the combination of a DOJ criminal investigation and severe industry-wide cost pressures, investors should exercise extreme caution, as the potential for significant regulatory penalties and further negative earnings revisions is high.
• Despite the stock's 40.2% year-to-date decline, its premium valuation relative to the industry suggests that the full extent of legal and operational risks may not be priced in, indicating potential for further downside.
• Investors should closely monitor developments in the DOJ probe and any disclosures on medical cost trends from both UNH and its peers, as these factors are the primary drivers of the sector's negative outlook and stock performance.